Screening assay for blood vessel maturation inhibitors

Chenglai Fu, Anita van der Zwan, Stephanie Gerber, Susan Van Den Berg, Elisa No, Wayne C.H.Wang, Nader Sheibani, Michael A. Carducci, Sushant Kachhap, Hans J. Hammers

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

In cancer patients, the development of resistance to anti-angiogenic agents targeting the VEGF pathway is common. Increased pericyte coverage of the tumor vasculature undergoing VEGF targeted therapy has been suggested to play an important role in resistance. Therefore, reducing the pericytes coverage of the tumor vasculature has been suggested to be a therapeutic approach in breaking the resistance to and increasing the efficacy of anti-angiogenic therapies. To screen compound libraries, a simple in vitro assay of blood vessel maturation demonstrating endothelial cells and pericytes association while forming lumenized vascular structures is needed. Unfortunately, previously described 3-dimensional, matrix based assays are laborious and challenging from an image and data acquisition perspective. For these reasons they generally lack the scalability needed to perform in a high-throughput environment. With this work, we have developed a novel in vitro blood vessel maturation assay, in which lumenized, vascular structures form in one optical plane and mesenchymal progenitor cells (10T1/2) differentiate into pericyte-like cells, which associate with the endothelial vessels (HUVECs). The differentiation of the 10T1/2 cells into pericyte-like cells is visualized using a GFP reporter controlled by the alpha smooth muscle actin promoter (SMP-8). The organization of these vascular structures and their recruited mural cells in one optical plane allows for automated data capture and subsequent image analysis. The ability of this assay to screen for inhibitors of pericytes recruitment was validated. In summary, this novel assay of in vitro blood vessel maturation provides a valuable tool to screen for new agents with therapeutic potential.

Original languageEnglish (US)
Pages (from-to)364-369
Number of pages6
JournalBiochemical and Biophysical Research Communications
Volume438
Issue number2
DOIs
StatePublished - Aug 23 2013

Fingerprint

Pericytes
Blood vessels
Blood Vessels
Assays
Screening
Vascular Endothelial Growth Factor A
Tumors
Data acquisition
Neoplasms
Image acquisition
Endothelial cells
Therapeutics
Mesenchymal Stromal Cells
Image analysis
Libraries
Smooth Muscle
Muscle
Scalability
Actins
Endothelial Cells

Keywords

  • Angiogenesis model
  • Blood vessel maturation
  • Drug screening
  • Endoglin
  • Imatinib
  • Pericyte
  • Sunitinib

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Screening assay for blood vessel maturation inhibitors. / Fu, Chenglai; van der Zwan, Anita; Gerber, Stephanie; Van Den Berg, Susan; No, Elisa; C.H.Wang, Wayne; Sheibani, Nader; Carducci, Michael A.; Kachhap, Sushant; Hammers, Hans J.

In: Biochemical and Biophysical Research Communications, Vol. 438, No. 2, 23.08.2013, p. 364-369.

Research output: Contribution to journalArticle

Fu, C, van der Zwan, A, Gerber, S, Van Den Berg, S, No, E, C.H.Wang, W, Sheibani, N, Carducci, MA, Kachhap, S & Hammers, HJ 2013, 'Screening assay for blood vessel maturation inhibitors', Biochemical and Biophysical Research Communications, vol. 438, no. 2, pp. 364-369. https://doi.org/10.1016/j.bbrc.2013.07.077
Fu C, van der Zwan A, Gerber S, Van Den Berg S, No E, C.H.Wang W et al. Screening assay for blood vessel maturation inhibitors. Biochemical and Biophysical Research Communications. 2013 Aug 23;438(2):364-369. https://doi.org/10.1016/j.bbrc.2013.07.077
Fu, Chenglai ; van der Zwan, Anita ; Gerber, Stephanie ; Van Den Berg, Susan ; No, Elisa ; C.H.Wang, Wayne ; Sheibani, Nader ; Carducci, Michael A. ; Kachhap, Sushant ; Hammers, Hans J. / Screening assay for blood vessel maturation inhibitors. In: Biochemical and Biophysical Research Communications. 2013 ; Vol. 438, No. 2. pp. 364-369.
@article{7a76de048ad34dea9aecc3417fef386d,
title = "Screening assay for blood vessel maturation inhibitors",
abstract = "In cancer patients, the development of resistance to anti-angiogenic agents targeting the VEGF pathway is common. Increased pericyte coverage of the tumor vasculature undergoing VEGF targeted therapy has been suggested to play an important role in resistance. Therefore, reducing the pericytes coverage of the tumor vasculature has been suggested to be a therapeutic approach in breaking the resistance to and increasing the efficacy of anti-angiogenic therapies. To screen compound libraries, a simple in vitro assay of blood vessel maturation demonstrating endothelial cells and pericytes association while forming lumenized vascular structures is needed. Unfortunately, previously described 3-dimensional, matrix based assays are laborious and challenging from an image and data acquisition perspective. For these reasons they generally lack the scalability needed to perform in a high-throughput environment. With this work, we have developed a novel in vitro blood vessel maturation assay, in which lumenized, vascular structures form in one optical plane and mesenchymal progenitor cells (10T1/2) differentiate into pericyte-like cells, which associate with the endothelial vessels (HUVECs). The differentiation of the 10T1/2 cells into pericyte-like cells is visualized using a GFP reporter controlled by the alpha smooth muscle actin promoter (SMP-8). The organization of these vascular structures and their recruited mural cells in one optical plane allows for automated data capture and subsequent image analysis. The ability of this assay to screen for inhibitors of pericytes recruitment was validated. In summary, this novel assay of in vitro blood vessel maturation provides a valuable tool to screen for new agents with therapeutic potential.",
keywords = "Angiogenesis model, Blood vessel maturation, Drug screening, Endoglin, Imatinib, Pericyte, Sunitinib",
author = "Chenglai Fu and {van der Zwan}, Anita and Stephanie Gerber and {Van Den Berg}, Susan and Elisa No and Wayne C.H.Wang and Nader Sheibani and Carducci, {Michael A.} and Sushant Kachhap and Hammers, {Hans J.}",
year = "2013",
month = "8",
day = "23",
doi = "10.1016/j.bbrc.2013.07.077",
language = "English (US)",
volume = "438",
pages = "364--369",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Screening assay for blood vessel maturation inhibitors

AU - Fu, Chenglai

AU - van der Zwan, Anita

AU - Gerber, Stephanie

AU - Van Den Berg, Susan

AU - No, Elisa

AU - C.H.Wang, Wayne

AU - Sheibani, Nader

AU - Carducci, Michael A.

AU - Kachhap, Sushant

AU - Hammers, Hans J.

PY - 2013/8/23

Y1 - 2013/8/23

N2 - In cancer patients, the development of resistance to anti-angiogenic agents targeting the VEGF pathway is common. Increased pericyte coverage of the tumor vasculature undergoing VEGF targeted therapy has been suggested to play an important role in resistance. Therefore, reducing the pericytes coverage of the tumor vasculature has been suggested to be a therapeutic approach in breaking the resistance to and increasing the efficacy of anti-angiogenic therapies. To screen compound libraries, a simple in vitro assay of blood vessel maturation demonstrating endothelial cells and pericytes association while forming lumenized vascular structures is needed. Unfortunately, previously described 3-dimensional, matrix based assays are laborious and challenging from an image and data acquisition perspective. For these reasons they generally lack the scalability needed to perform in a high-throughput environment. With this work, we have developed a novel in vitro blood vessel maturation assay, in which lumenized, vascular structures form in one optical plane and mesenchymal progenitor cells (10T1/2) differentiate into pericyte-like cells, which associate with the endothelial vessels (HUVECs). The differentiation of the 10T1/2 cells into pericyte-like cells is visualized using a GFP reporter controlled by the alpha smooth muscle actin promoter (SMP-8). The organization of these vascular structures and their recruited mural cells in one optical plane allows for automated data capture and subsequent image analysis. The ability of this assay to screen for inhibitors of pericytes recruitment was validated. In summary, this novel assay of in vitro blood vessel maturation provides a valuable tool to screen for new agents with therapeutic potential.

AB - In cancer patients, the development of resistance to anti-angiogenic agents targeting the VEGF pathway is common. Increased pericyte coverage of the tumor vasculature undergoing VEGF targeted therapy has been suggested to play an important role in resistance. Therefore, reducing the pericytes coverage of the tumor vasculature has been suggested to be a therapeutic approach in breaking the resistance to and increasing the efficacy of anti-angiogenic therapies. To screen compound libraries, a simple in vitro assay of blood vessel maturation demonstrating endothelial cells and pericytes association while forming lumenized vascular structures is needed. Unfortunately, previously described 3-dimensional, matrix based assays are laborious and challenging from an image and data acquisition perspective. For these reasons they generally lack the scalability needed to perform in a high-throughput environment. With this work, we have developed a novel in vitro blood vessel maturation assay, in which lumenized, vascular structures form in one optical plane and mesenchymal progenitor cells (10T1/2) differentiate into pericyte-like cells, which associate with the endothelial vessels (HUVECs). The differentiation of the 10T1/2 cells into pericyte-like cells is visualized using a GFP reporter controlled by the alpha smooth muscle actin promoter (SMP-8). The organization of these vascular structures and their recruited mural cells in one optical plane allows for automated data capture and subsequent image analysis. The ability of this assay to screen for inhibitors of pericytes recruitment was validated. In summary, this novel assay of in vitro blood vessel maturation provides a valuable tool to screen for new agents with therapeutic potential.

KW - Angiogenesis model

KW - Blood vessel maturation

KW - Drug screening

KW - Endoglin

KW - Imatinib

KW - Pericyte

KW - Sunitinib

UR - http://www.scopus.com/inward/record.url?scp=84882579515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882579515&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2013.07.077

DO - 10.1016/j.bbrc.2013.07.077

M3 - Article

C2 - 23892038

AN - SCOPUS:84882579515

VL - 438

SP - 364

EP - 369

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 2

ER -